49 results on '"Kaunitz, Andrew M"'
Search Results
2. Surgical menopause: health implications and hormonal management
3. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial
4. The National Academies of Science, Engineering, and Medicine (NASEM) Report on Compounded Bioidentical Hormone Therapy
5. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial
6. In Reply
7. The Womenʼs Health Initiative trials of menopausal hormone therapy: lessons learned
8. Hormone therapy and sarcopenia: implications for the prevention of frailty as women age
9. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia
10. Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices
11. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms
12. Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women
13. Women harmed by vaginal laser for treatment of GSM—the latest casualties of fear and confusion surrounding hormone therapy
14. Not time to abandon use of local vaginal hormone therapies
15. Contraception for midlife women: a review
16. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Womenʼs Sexual Health
17. Screening mammography for average-risk women
18. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Womenʼs Health Initiative Observational Study
19. Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance
20. Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Womenʼs Health Initiative Observational Study
21. Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative
22. Maintaining cognitive function in surgically menopausal women: the importance of estrogen
23. Surgical menopause: health implications and hormonal management
24. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms
25. Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women
26. Hormonal contraception and risk of breast cancer: a closer look
27. Concern about US Preventive Services Task Force recommendation on hormone therapy for the primary prevention of chronic conditions in postmenopausal women
28. Menopausal hormone therapy and national time trends in mortality: cautions regarding causal inference
29. The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women
30. Use of systemic hormone therapy in BRCA mutation carriers
31. Clinical trials of new treatments for menopausal conditions: paying attention to race
32. Compounded bioidentical hormone therapy
33. Failure to treat menopausal symptoms
34. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older
35. Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making
36. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause
37. Why the product labeling for low-dose vaginal estrogen should be changed
38. Extended duration use of menopausal hormone therapy
39. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women
40. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms
41. Should new-onset arthralgia be considered a menopausal symptom?
42. Disparity in menopausal hormone therapy use between women obstetrician gynecologists and women overall
43. Letters to the Editor
44. Transdermal and vaginal estradiol for the treatment of menopausal symptoms
45. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy
46. Effective herbal treatment of vasomotor symptoms-are we any closer?
47. Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata
48. Hormone therapy and breast cancer risk: trumping fear with facts
49. Use of systemic hormone therapy in BRCAmutation carriers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.